First human trial launches for 'KIND t Cells' targeting deadly childhood brain cancer
NCT ID NCT05478837
Summary
This is a first-in-human safety study for a new cell therapy called KIND T cells. It is for children and young adults (ages 2-25) with a specific, hard-to-treat brain tumor called H3.3K27M-mutated diffuse midline glioma. Doctors take a patient's own immune cells, genetically modify them in a lab to better target the tumor, and then infuse them back after a short course of chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.